Obstetrics and GynecologyObstetrics and GynecologyАкушерство и гинекология0300-90922412-5679Bionika Media45647810.18565/aig.2022.315ReviewsОбзорыReview ArticleImpact of hormone therapy on the overall and relapse-free survival of patients receiving treatment for ovarian cancerВлияние гормональной терапии на общую и безрецидивную выживаемость больных, перенесших лечение по поводу злокачественных новообразований яичниковhttps://orcid.org/0000-0002-4654-9512BabaevaNataliya А.БабаеваНаталия Александровна
Russian Federation

Dr. Sci. Med., oncologist, Leading Researcher at the Instititute of Gynecological Oncology and Mammology

д.м.н., врач-онколог, онкологическое отделение хирургических методов лечения, в.н.с. Института онкогинекологии и маммологии

natbabaeva@yandex.ruhttps://orcid.org/0000-0003-2864-066XYurenevaSvetlana V.ЮреневаСветлана Владимировна
Russian Federation

Dr. Sci. Med., obstetrician-gynecologist, oncologist, Deputy Director for Science of the Instititute of Gynecological Oncology and Mammology

д.м.н., врач акушер-гинеколог, онколог, заместитель директора по науке Институт онкогинекологии и маммологии

syureneva@gmail.comhttps://orcid.org/0000-0002-2957-3940AleshikovaOlga I.АлешиковаОльга Ивановна
Russian Federation

Ph.D., oncologist, Senior Researcher at the Instititute of Gynecological Oncology and Mammology

к.м.н., врач-онколог, онкологическое отделение хирургических методов лечения, с.н.с. Института онкогинекологии и маммологии

olga.aleshikova@gmail.comhttps://orcid.org/0000-0002-7430-1207YakushevskayaOksana V.ЯкушевскаяОксана Владимировна
Russian Federation

Ph.D., obstetrician-gynecologist, oncologist, Researcher at the Department of Gynecological Endocrinology

к.м.н., врач акушер-гинеколог, онколог, н.с. отделения гинекологической эндокринологии

ykushox83@mail.ruhttps://orcid.org/0000-0001-6396-4948AshrafyanLevon A.АшрафянЛевон Андреевич
Russian Federation

Academician of the RAS, Professor, Dr. Sci. Med., Director of the Instititute of Gynecological Oncology and Mammology

д.м.н., профессор, академик РАН, директор Института онкогинекологии и маммологии

levaa2004@yahoo.comAcademician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of RussiaФГБУ «Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова» Министерства здравоохранения Российской Федерации30052023440482405202324052023Copyright ©; 2023, Bionika MediaCopyright ©; 2023, ООО «Бионика Медиа»2023Bionika MediaООО «Бионика Медиа»https://journals.eco-vector.com/0300-9092/article/view/456478

Objective: To analyze the literature data on the possibility of using different variants of hormone therapy in patients who previously underwent treatment for ovarian malignancies, oncofertility and the effect of hormone therapy on the overall and relapse-free survival of patients with different morphological variants of ovarian malignancies. The review includes the data from foreign and Russian publications in PubMed on this issue over the past ten years. This was an analysis of the possibilities and contraindications to the use of hormone therapy, as well as menopausal hormone therapy in women with different morphological variants of ovarian malignancies. It was concluded that hormone therapy can be used in patients with a history of ovarian cancer, non-epithelial malignant tumors and borderline ovarian tumors.

Conclusion: The correlation between the use of hormone therapy and the risk of recurrence of neoplasms in women treated for ovarian cancer has been clearly established only for granulocellular ovarian tumors and serous tumors of low malignant potential. In case of other morphological variants of ovarian malignancies, menopausal hormone therapy should be prescribed very carefully. Before making a decision on the use of hormone therapy for each patient, it is necessary to conduct a thorough examination and consult an interdisciplinary group of specialists in order to individualize the hormone therapy plan based on the assessment of the potential risks and benefits of the treatment.

Цель работы – анализ данных литературных источников о возможности использования различных вариантов гормональной терапии у пациенток, проводивших ранее лечение злокачественных новообразований яичников, онкофертильности и влиянии гормональной терапии на общую и безрецидивную выживаемость больных с различными морфологическими вариантами злокачественных новообразований яичников. В обзор включены данные зарубежных и отечественных публикаций в PubMed по данной теме за последние 10 лет. Проанализированы возможности и противопоказания к применению гормональной терапии, а также менопаузальной гормональной терапии у женщин при различных морфологических вариантах злокачественных новообразований яичников. Сделано заключение о возможности применения гормональной терапии у пациенток с наличием в анамнезе рака яичников, неэпителиальных злокачественных опухолей и пограничных опухолей яичников.

Заключение: Взаимосвязь между использованием гормональной терапии и риском рецидива новообразования у женщин, получавших лечение по поводу злокачественных опухолей яичников, четко установлена лишь для гранулезоклеточных опухолей яичников и серозных опухолей низкой степени злокачественности. При других морфологических вариантах злокачественных новообразований яичников назначение менопаузальной гормональной терапии возможно с высокой долей осторожности. Перед принятием решения об использовании гормонотерапии в обязательном порядке должно быть проведено тщательное обследование и консультирование каждой пациентки на междисциплинарном консилиуме с целью индивидуализации плана проведения гормональной терапии на основе оценки потенциальных рисков и преимуществ предполагаемой терапии.

ovarian cancerborderline ovarian tumorsgerminal ovarian tumorssex cord-stromal tumorsmenopausal hormone therapyoncological risksoverall and relapse-free survivalрак яичниковпограничные опухоли яичниковгерминогенные опухоли яичниковопухоли стромы полового тяжаменопаузальная гормональная терапияонкологические рискиобщая и безрецидивная выживаемостьMinami C.A., Freedman R.A. Menopausal hormone therapy and long-term breast cancer risk: Further Data From the Women's Health Initiative Trials. JAMA. 2020; 324(4): 347-9. https://dx.doi.org/10.1001/jama.2020.9620.Crawford S.L., Sybil L. Hormone therapy and vasomotor symptoms after the Women’s Health Initiative. Menopause. 2014; 21(5): 439-41. https://dx.doi.org/10.1097/GME.0000000000000228.Chlebowski R.T., Anderson G.L., Aragaki A.K., Manson J.E., Stefanick M.L. Pan K. et al. Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women’s Health Initiative Randomized Clinical Trials. JAMA. 2020; 324(4): 369-80. https://dx.doi.org/10.1001/jama.2020.9482.The National Institute for Health and Care Excellence. Menopause: diagnosis and management NICE guideline [NG23] Published date: November 2015 Last updated: December 2019. Available at: https://www.nice.org.uk/guidance/ng23. Accessed 7 January 2020.de Villiers T.J., Hall J.E., Pinkerton J.V., Pérez S.C., Rees M., Yang C., Pierroz D.D. et al. Revised global consensus statement on menopausal hormone therapy. Maturitas. 2016; 91: 153-5. https://dx.doi.org/10.1016/j.maturitas.2016.06.001.Armeni E., Lambrinoudaki I., Ceausu I., Depypere H., Mueck A., Pérez-López F.R. et al. Maintaining postreproductive health: a care pathway from the European Menopause and Andropause Society (EMAS). Maturitas. 2016; 89: 63-72. https://dx.doi.org/10.1016/j.maturitas.2016.04.013.Shifren J.L., Gass M.L. NAMS recommendations for clinical care of midlife women working group. The north american menopause society recommendations for clinical care of midlife women. Menopause. 2014; 121(10): 1038-62. https://dx.doi.org/10.1097/GME.0000000000000319.Cobin R.H., Goodman N.F. AACE reproductive endocrinology scientific committee. American Association of Clinical Endocrinologists and American College of Endocrinology position statement on menopause-2017 update. Endocr. Pract. 2017; 23(7): 869-80. https://dx.doi.org/10.4158/EP171828.PS.Pickar J.H., Boucher M., Morgenstern D. Tissue selective estrogen complex (TSEC): a review. Menopause. 2018; 25(9): 1033-45. https://dx.doi.org/10.1097/GME.0000000000001095.Di Donato V., Schiavi M.C., Iacobelli V., D'oria O., Kontopantelis E., Simoncini T. et al. Ospemifene for the treatment of vulvar and vaginal atrophy: a meta-analysis of randomized trials. Part II: evaluation oftolerability and safety. Maturitas. 2019; 121: 93-100. https://dx.doi.org/10.1016/j.maturitas.2018.11.017.Yakushevskaya O.V., Babaeva N.A., Yureneva S.V., Ashrafyan L.A. Impact of menopausal hormone therapy on the development and progression of cervical and endometrial cancers. Obstetrics and Gynecology. 2022; (8): 30-5. (in Russian). https://dx.doi.org/10.18565/aig.2022.8.30-35.Якушевская О.В., Бабаева Н.А., Юренева С.В., Ашрафян Л.А. Влияние менопаузальной гормональной терапии на развитие и прогрессирование рака шейки матки и эндометрия; Акушерство и гинекология. 2022; 8: 30-5. https://dx.doi.org/10.18565/aig.2022.8.30-35.Sung H., Ferlay J., Siegel R.L. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021; 71(3): 209-49. https://dx.doi.org/ 10.3322/caac.21660.Momenimovahed Z., Tiznobaik A., Taheri S., Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. Int. J. Womens Health. 2019; 11: 287-99. https://dx.doi.org/10.2147/IJWH.S197604.Ferlay J., Soerjomataram I., Dikshit R., Eser S., Mathers C., Rebelo M. et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer. 2015; 136(5): E359-86. https://dx.doi.org/10.1002/ijc.29210.Krugmann J., Schwarz C.L., Melcher B., Sterlacci W.,Ozalinskaite A., Lermann J. et al. Malignant ascites occurs most often in patients with high-grade serous papillary ovarian cancer at initial diagnosis: a retrospective analysis of 191 women treated at Bayreuth Hospital, 2006-2015. Arch. Gynecol. Obstet. 2019; 299(2): 515-23. https://dx.doi.org/10.1007/s00404-018-4952-9Gaona-Luviano P., Medina-Gaona L.A., Magaña-Pérez K. Epidemiology of ovarian cancer. Chin. Clin. Oncol. 2020; 9(4): 47. https://dx.doi.org/10.21037/cco-20-34.Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018; 68(6): 394-424. https://dx.doi.org/10.3322/caac.21492.Kaprin A.D., Starinsky V.V., Shakhzadova A.O., eds. Malignant neoplasms in Russia in 2020 (morbidity and mortality). Moscow; 2021. 252p. (in Russian).Каприн А.Д., Старинский В.В., Шахзадова А.О., ред. Злокачественные новообразования в России в 2020 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена – филиал ФГБУ "НМИЦ радиологии" Минздрава России; 2021. 252с.Gotlieb W.H., Chetrit A., Menczer J., Hirsh-Yechezkel G., Lubin F. et al. Demographic and genetic characteristics of patients with borderline ovarian tumors as compared to early stage invasive ovarian cancer. Gynecol. Oncol. 2005; 97(3): 780-3. https://dx.doi.org/10.1016/j.ygyno.2005.02.022.Koshiyama M., Matsumura N., Konishi I. Recent concepts of ovarian carcinogenesis: Type I and Type II. Biomed. Res. Int. 2014; 2014: 934261. https://dx.doi.org/10.1155/2014/934261.Lim D., Oliva E. Precursors and pathogenesis of ovarian carcinoma. Pathology. 2013; 45(3): 229-42. https://dx.doi.org/10.1097/PAT.0b013e32835f2264.Kurman R.J., Shih I.-M. The Dualistic model of ovarian carcinogenesis: revisited, revised and expanded. Am. J. Pathol. 2016; 186(4): 733-47. https://dx.doi.org/10.1016/j.ajpath.2015.11.011.Bowtell D.D., Böhm S., Ahmed A.A., Aspuria P.-J., Bast R.C. Jr et al. Rethinking ovarian cancer II: Reducing mortality from high-grade serous ovarian cancer. Nat. Rev. Cancer. 2015; 15(11): 668-79. https://dx.doi.org/10.1038/nrc4019.Beral V., Gaitskell K., Hermon C., Moser K., Reeves G., Peto R.; Collaborative Group On Epidemiological Studies of Ovarian Cancer. Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet. 2015; 385(9980): 1835-42. https://dx.doi.org/10.1016/S0140-6736(14)61687-1.Rodriguez C., Eugenia E. Calle E.E., Coates R.J., Miracle-McMahill H.L., Thun M.J., Heath C.W. Jr. Estrogen replacement therapy and fatal ovarian cancer. Am. J. Epidemiol. 1995; 141(9): 828-35. https://dx.doi.org/10.1093/oxfordjournals.aje.a117518.Guidozzi F., Daponte A. Estrogen replacement therapy for ovarian carcinoma survivors: a randomised control trial. Cancer. 1999; 86(6): 1013-8. https://dx.doi.org/10.1002/(sici)1097-0142(19990915)86:6<1013::aid-cncr17>3.0.co;2-1.Eeles R.A., Morden J.P., Gore M., Mansi J., Glees J, Wenczl M. et al. Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: results of the AHT randomized trial. J. Clin. Oncol. 2015; 33(35): 4138-44. https://dx.doi.org/10.1200/JCO.2015.60.9719.Eeles R.A., Tan S., Wiltshaw E., Fryatt I., A'Hern R.P., Shepherd J.H., Harmer C.L. et al. Hormone replacement therapy and survival after surgery for ovarian cancer. BMJ. 1991; 259-62. https://dx.doi.org/1010.1136/bmj.302.6771.259.Bebar S., Ursic-Vrscaj M. Hormone replacement therapy after epithelial ovarian cancer treatment. Eur. J. Gynecol. Oncol. 2000; 21(2): 192-6.Ursic-Vrscaj M., Bebar S., Zakelj M.P. Hormone replacement therapy after invasive ovarian cystadenocarcinoma treatment: the effect on survival. Menopause. 2001; 8(1): 70-5. https://dx.doi.org/10.1097/ 00042192-200101000-00012.Mascarenhas C., Lambe M., Bellocco R., Bergfeldt K., Riman T., Persson I., Weiderpass E. Use of hormone replacement therapy before and after ovarian cancer diagnosis and ovarian cancer survival. Int. J. Cancer. 2006; 119(12): 2907-15. https://dx.doi.org/10.1002/ijc.22218.Power L., Lefas G., Lambert P., Kim D., Evaniuk D., Lotocki R. et al. Hormone use after nonserous epithelial ovarian cancer: overall and disease-free survival. Obstet. Gynecol. 2016; 127(5): 837-47. https://dx.doi.org/10.1097/AOG.0000000000001396.Li D., Ding C.-Y., Qiu L.-H. Postoperative hormone replacement therapy for epithelial ovarian cancer patients: a systematic review and meta-analysis. Gynecol. Oncol. 2015; 139(2): 355-62. https://dx.doi.org/10.1016/ j.ygyno.2015.07.109.Zhang Y.L., Chen J.H., Lu W., Li Bl.L., Zhu Q.Y., Wan X.P. Efficacy of postoperative hormone replacement therapy on prognosis of patients with serous ovarian carcinoma. Chin. Med. J. (Engl). 2016; 129(11): 1316-21. https://dx.doi.org/10.4103/0366-6999.182835.Wentzensen N., Trabert B. Hormone therapy: short-term relief, long-term consequences. Lancet. 2015; 385(9980): 1806-8. https://dx.doi.org/10.1016/S0140-6736(14)62458-2.Rousset-Jablonski C., Selle F., Adda-Herzog E., Planchamp F., Selleret L., Pomel C. et al. Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumours: guidelines from the French national network dedicated to rare gynaecological cancers. Eur. J. Cancer. 2019; 116: 35-44. https://dx.doi.org/10.1016/j.ejca.2019.04.018.Gershenson D.M., Bodurka D.C., Coleman R.L., Lu K.H., Malpica A., Sun C.C. Hormonal maintenance therapy for women with low-grade serous cancer of the ovary or peritoneum. J. Clin. Oncol. 2017; 35(10): 1103-11. https://dx.doi.org/10.1200/JCO.2016.71.0632.